Reconsidering biologic treatment recommendations for CRSwNP without asthma in EUFOREA guidelines
Rhinology Journal · 01.03.2026 · 0-0
DOI: 10.4193/rhin25.359 ↗Kurz gefasst
Leitlinie in der Zeitschrift Rhinology Journal, online erschienen am 01.03.2026. Verfasst von J Oppenheimer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Medicine and Dentistry of New Jersey/Rutgers New Jersey Medical School, Newark, NJ, USA. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Biological Products.
Abstract (Originalsprache)
The recently published EUFOREA pocket guide “Biologics in Upper and Lower Airway Diseases” summarises recommendati-ons on the use of biologics in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma (1) and offers advice on biologic choice for practicing clinicians. The creation of this pocket guide, in the absence of any head-to-head studies at that time, drew on expert opinions and published indirect treatment compari-son (ITC) approaches (2,3). It makes a single recommendation for a preferred biologic, in patients affected by CRSwNP, without concomitant asthma (apart from specific cases such as pregnan-cy), whilst offering different options in asthma endotypes and phenotypes. We wish to draw the attention of the readership to some additional considerations relating to biologic choice for these diseases and how they are classified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Medicine and Dentistry of New Jersey/Rutgers New Jersey Medical School, Newark, NJ, USA.
- Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy;Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Department of Respiratory Diseases, Aix-Marseille University, Marseille, France.
- Rhinology and Skull Base Unit, Department of Otolaryngology, University Hospital Virgen del Rocio, Seville, Spain;Department of Surgery, University of Seville, Seville, Spain.
- Global Medical Affairs, GSK, London, UK.
- Respiratory Biologics, GSK, Athens, Greece.
Zitieren
APA
Oppenheimer, J., Canonica, G. W., Chanez, P., Maza-Solano, J., Tacon, C., Kallinikou, K., Howarth, P., Bonini, M., Eguiluz-Gracia, I., & Bourdin, A. (2026). Reconsidering biologic treatment recommendations for CRSwNP without asthma in EUFOREA guidelines. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin25.359
Vancouver
Oppenheimer J, Canonica GW, Chanez P, Maza-Solano J, Tacon C, Kallinikou K, et al. Reconsidering biologic treatment recommendations for CRSwNP without asthma in EUFOREA guidelines. Rhinology Journal. 2026;0(0):0-0. doi:10.4193/rhin25.359
BibTeX
@article{Oppenheimer2026,
author = {Oppenheimer, J and Canonica, G W and Chanez, P and Maza-Solano, J and Tacon, C and Kallinikou, K and Howarth, P and Bonini, M and Eguiluz-Gracia, I and Bourdin, A},
title = {Reconsidering biologic treatment recommendations for CRSwNP without asthma in EUFOREA guidelines},
journal = {Rhinology Journal},
year = {2026},
volume = {0},
number = {0},
pages = {0--0},
doi = {10.4193/rhin25.359}
}
EUVIMED